###begin article-title 0
HLA-class I markers and multiple sclerosis susceptibility in the Italian population
###end article-title 0
###begin p 1
This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Licence. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
###end p 1
###begin p 2
###xml 110 118 110 118 <italic>HLA-A*02</italic>
###xml 120 129 120 129 <italic>HLA-Cw*05</italic>
###xml 134 142 134 142 <italic>MOG-142L</italic>
###xml 195 199 195 199 <italic>A*02</italic>
###xml 204 209 204 209 <italic>Cw*05</italic>
###xml 300 307 300 307 <italic>MOG-142</italic>
###xml 388 396 388 396 <italic>HLA-A*02</italic>
###xml 506 507 506 507 <italic>P</italic>
###xml 510 512 510 512 <sup>&#8722;9</sup>
###xml 540 547 540 547 <italic>DRB1*15</italic>
###xml 565 570 565 570 <italic>DRB1*</italic>
###xml 721 729 721 729 <italic>MOG-142L</italic>
###xml 779 783 779 783 <italic>A*02</italic>
###xml 785 790 785 790 <italic>Cw*05</italic>
###xml 902 911 902 911 <italic>HLA-A*02-</italic>
###xml 944 948 944 948 <italic>DRB1</italic>
###xml 970 974 970 974 <italic>A*02</italic>
###xml 978 984 978 984 <italic>Cw*05-</italic>
###xml 1062 1068 1062 1068 <italic>Cw*05-</italic>
###xml 1134 1135 1134 1135 <italic>P</italic>
###xml 1145 1147 1145 1147 <sup>&#8722;5</sup>
###xml 1219 1223 1219 1223 <italic>A*02</italic>
###xml 1225 1230 1225 1230 <italic>Cw*05</italic>
###xml 1290 1297 1290 1297 <italic>DRB1*03</italic>
###xml 1308 1309 1308 1309 <italic>P</italic>
###xml 1335 1340 1335 1340 <italic>Cw*05</italic>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
Previous studies reported an association with multiple sclerosis (MS) of distinct HLA-class I markers, namely HLA-A*02, HLA-Cw*05 and MOG-142L. In this work, we tested the association with MS of A*02 and Cw*05 in 1273 Italian MS patients and 1075 matched controls, which were previously analyzed for MOG-142, and explored the relationship among these three markers in modulating MS risk. HLA-A*02 conferred a statistically robust MS protection (odds ratio, OR=0.61; 95% confidence intervals, CI=0.51-0.72, P<10-9), which was independent of DRB1*15 and of any other DRB1* allele and remained similar after accounting for the other two analyzed class I markers. Conversely, the protective effect we previously observed for MOG-142L was secondary to its linkage disequilibrium with A*02. Cw*05 was not associated considering the whole sample, but its presence significantly enhanced the protection in the HLA-A*02-positive group, independently of DRB1: the OR conferred by A*02 in Cw*05-positive individuals (0.22, 95% CI=0.13-0.38) was significantly lower than in Cw*05-negative individuals (0.69, 95% CI=0.58-0.83) with a significant (P=4.94 x 10-5) multiplicative interaction between the two markers. In the absence of A*02, Cw*05 behaved as a risk factor, particularly in combination with DRB1*03 (OR=3.89, P=0.0006), indicating that Cw*05 might be a marker of protective or risk haplotypes, respectively.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 182 183 182 183 <xref ref-type="other" rid="bib1">1</xref>
###xml 182 183 182 183 <sup><xref ref-type="other" rid="bib1">1</xref></sup>
###xml 310 311 310 311 <xref ref-type="other" rid="bib2">2</xref>
###xml 310 311 310 311 <sup><xref ref-type="other" rid="bib2">2</xref></sup>
###xml 544 567 544 567 <italic>HLA DRB1*1501-DQB1*0602</italic>
###xml 583 587 583 587 <italic>DR15</italic>
###xml 641 642 641 642 <xref ref-type="other" rid="bib3">3</xref>
###xml 641 642 641 642 <sup><xref ref-type="other" rid="bib3">3</xref></sup>
###xml 684 685 684 685 <xref ref-type="other" rid="bib4">4</xref>
###xml 687 688 687 688 <xref ref-type="other" rid="bib5">5</xref>
###xml 690 691 690 691 <xref ref-type="other" rid="bib6">6</xref>
###xml 684 691 684 691 <sup><xref ref-type="other" rid="bib4">4</xref>, <xref ref-type="other" rid="bib5">5</xref>, <xref ref-type="other" rid="bib6">6</xref></sup>
###xml 691 695 691 695 <italic>DR15</italic>
###xml 393 398 <span type="species:ncbi:9606">human</span>
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by disseminated and focal damage of myelin and axons, resulting in a disabling condition.1 The pathogenesis of MS is not understood yet, but several studies suggest an interaction of environmental and genetic factors.2 The genetic factor showing the strongest association with MS is localized in the human Major Histocompatibility complex (HLA) region on chromosome 6p21.3. The risk haplotype that has been identified for the Caucasian populations is HLA DRB1*1501-DQB1*0602 (also known as DR15 haplotype) in the HLA-class II region. In the Italian3 as well as in other European populations,4, 5, 6DR15 confers an odds ratio (OR) of about 3.
###end p 4
###begin p 5
###xml 141 150 141 150 <italic>HLA-DRB1.</italic>
###xml 211 217 211 217 <italic>et al.</italic>
###xml 217 218 217 218 <xref ref-type="other" rid="bib7">7</xref>
###xml 217 218 217 218 <sup><xref ref-type="other" rid="bib7">7</xref></sup>
###xml 467 476 467 476 <italic>HLA-DRB1.</italic>
###xml 476 477 476 477 <xref ref-type="other" rid="bib8">8</xref>
###xml 476 477 476 477 <sup><xref ref-type="other" rid="bib8">8</xref></sup>
###xml 585 593 585 593 <italic>HLA-DRB1</italic>
###xml 604 610 604 610 <italic>et al.</italic>
###xml 610 611 610 611 <xref ref-type="other" rid="bib9">9</xref>
###xml 610 611 610 611 <sup><xref ref-type="other" rid="bib9">9</xref></sup>
###xml 748 750 748 750 <xref ref-type="other" rid="bib10">10</xref>
###xml 748 750 748 750 <sup><xref ref-type="other" rid="bib10">10</xref></sup>
###xml 769 770 769 770 <sup>*</sup>
###xml 816 817 816 817 <italic>P</italic>
###xml 824 827 824 827 <sup>&#8722;12</sup>
###xml 834 840 834 840 <italic>et al.</italic>
###xml 840 842 840 842 <xref ref-type="other" rid="bib11">11</xref>
###xml 840 842 840 842 <sup><xref ref-type="other" rid="bib11">11</xref></sup>
###xml 910 919 910 919 <italic>HLA-Cw*05</italic>
###xml 1001 1002 1001 1002 <italic>P</italic>
###xml 1011 1013 1011 1013 <sup>&#8722;5</sup>
###xml 1056 1060 1056 1060 <italic>DRB1</italic>
###xml 1208 1213 1208 1213 <italic>V142L</italic>
###xml 1341 1346 1341 1346 <italic>HLA-A</italic>
###xml 1360 1365 1360 1365 <italic>HLA-C</italic>
###xml 1375 1377 1375 1377 <xref ref-type="other" rid="bib12">12</xref>
###xml 1375 1377 1375 1377 <sup><xref ref-type="other" rid="bib12">12</xref></sup>
###xml 1382 1386 1382 1386 <italic>142L</italic>
###xml 1395 1404 1395 1404 <italic>MOG-142L)</italic>
###xml 1489 1492 1489 1492 <italic>HLA</italic>
###xml 1493 1500 1493 1500 <italic>DRB1*15</italic>
###xml 1516 1518 1516 1518 <xref ref-type="other" rid="bib12">12</xref>
###xml 1516 1518 1516 1518 <sup><xref ref-type="other" rid="bib12">12</xref></sup>
###xml 1527 1533 1527 1533 <italic>et al.</italic>
###xml 1533 1535 1533 1535 <xref ref-type="other" rid="bib13">13</xref>
###xml 1533 1535 1533 1535 <sup><xref ref-type="other" rid="bib13">13</xref></sup>
###xml 1641 1649 1641 1649 <italic>HLA-A*02</italic>
###xml 1739 1747 1739 1747 <italic>MOG-142L</italic>
###xml 1748 1750 1748 1750 <xref ref-type="other" rid="bib13">13</xref>
###xml 1748 1750 1748 1750 <sup><xref ref-type="other" rid="bib13">13</xref></sup>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
###xml 1119 1127 <span type="species:ncbi:9606">patients</span>
In recent years, several studies have searched for the presence of MS susceptibility factors in the HLA region with an effect independent of HLA-DRB1. No evidence of an HLA-A or -B association was found by Chao et al.7 in 294 Canadian families. Moreover, none of the 1068 single-nucleotide-polymorphisms (SNPs) from a high-density panel spanning the entire HLA genomic region showed additional association in 1185 Canadian and Finnish families after conditioning for HLA-DRB1.8 Conversely, other studies have detected the effect at least of one class I genetic factor independently of HLA-DRB1. Brynedal et al.9 confirmed in a Nordic cohort of 1084 MS patients and 1347 controls the results of a previous study performed in a smaller Swedish panel,10 showing that HLA-A*02 is negatively associated with MS (OR=0.63, P=7 x 10-12). Yeo et al.11 analyzed over 1600 UK MS patients and 3600 controls and found that HLA-Cw*05 exerts an MS-protective effect (OR=0.49, 95% confidence intervals, CI=0.34-0.69, P=3.3 x 10-5) after excluding all individuals carrying DRB1 alleles associated with MS. In a panel of 1124 Italian MS patients and 1136 controls, we found a significant association with the missense variant V142L (rs2857766) in the gene encoding the Myelin Oligodendrocyte Glycoprotein (MOG) mapping in the HLA-class I region, telomeric to HLA-A (0.3 Mb) and HLA-C (1.6 Mb).12 The 142L allele (MOG-142L) conferred an OR=0.70 (95% C.I=0.60-0.82) that remained similar after accounting for HLA-DRB1*15 carrier status.12 Burfoot et al.13 showed similar data in a small Tasmanian population. Moreover, they reported a negative association with HLA-A*02, but they did not analyze if this variation was primarily associated or was dependent on MOG-142L.13
###end p 5
###begin p 6
###xml 63 67 63 67 <italic>A*02</italic>
###xml 69 84 69 84 <italic>Cw*05, MOG-142L</italic>
The relationship among the three reported HLA-class I markers, A*02, Cw*05, MOG-142L and their association with MS has not been examined so far.
###end p 6
###begin p 7
###xml 43 47 43 47 <italic>A*02</italic>
###xml 52 57 52 57 <italic>Cw*05</italic>
###xml 156 163 156 163 <italic>MOG-142</italic>
###xml 217 225 217 225 <italic>MOG-142L</italic>
###xml 227 235 227 235 <italic>HLA-A*02</italic>
###xml 240 249 240 249 <italic>HLA-Cw*05</italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
In this work, we tested the association of A*02 and Cw*05 in a large cohort of Italian MS patients and controls, most of whom had been previously typed for MOG-142 polymorphism, and we explored the relationship among MOG-142L, HLA-A*02 and HLA-Cw*05 in modulating MS risk.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 38 39 38 39 <sup>*</sup>
###xml 52 53 52 53 <sup>*</sup>
Association with MS of MOG-142L, HLA-A*02 and HLA-Cw*05 in the Italian population
###end title 9
###begin p 10
###xml 22 30 22 30 <italic>MOG-142L</italic>
###xml 32 40 32 40 <italic>HLA-A*02</italic>
###xml 45 54 45 54 <italic>HLA-Cw*05</italic>
###xml 91 98 91 98 <xref rid="tbl1" ref-type="table">Table 1</xref>
###xml 118 126 118 126 <italic>MOG-142L</italic>
###xml 131 140 131 140 <italic>HLA-A*02-</italic>
###xml 265 266 265 266 <xref ref-type="other" rid="bib9">9</xref>
###xml 268 270 268 270 <xref ref-type="other" rid="bib10">10</xref>
###xml 272 274 272 274 <xref ref-type="other" rid="bib12">12</xref>
###xml 276 278 276 278 <xref ref-type="other" rid="bib13">13</xref>
###xml 265 278 265 278 <sup><xref ref-type="other" rid="bib9">9</xref>, <xref ref-type="other" rid="bib10">10</xref>, <xref ref-type="other" rid="bib12">12</xref>, <xref ref-type="other" rid="bib13">13</xref></sup>
###xml 308 313 308 313 <italic>Cw*05</italic>
###xml 416 424 416 424 <italic>MOG-142L</italic>
###xml 432 440 432 440 <italic>HLA-A*02</italic>
###xml 542 546 542 546 <italic>142L</italic>
###xml 581 585 581 585 <italic>A*02</italic>
###xml 635 639 635 639 <italic>142L</italic>
###xml 674 678 674 678 <italic>A*02</italic>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
The MS association of MOG-142L, HLA-A*02 and HLA-Cw*05 was tested in a case-control study (Table 1). The frequency of MOG-142L and HLA-A*02-positive individuals was significantly lower in cases than in controls, confirming the previously reported protective effect,9, 10, 12, 13 whereas the association with Cw*05 was not significant. The comparison of genotype frequencies suggested a dominant-protective effect of MOG-142L and of HLA-A*02, as their frequency was significantly decreased both among homozygous (OR=0.55, 95% CI=0.34-0.89 for 142L and OR=0.55, 95% CI=0.37-0.82 for A*02) and heterozygous (OR=0.75, 95% CI=0.62-0.90 for 142L and OR=0.68, 95% CI=0.57-0.81 for A*02) MS patients. The results did not change after adjustment for sex and were not different among male and female cases in a stratified analysis (data not shown). The results were not significantly different in relapsing remitting and primary progressive patients (data not shown).
###end p 10
###begin p 11
###xml 81 92 81 92 <italic>HLA-DRB1*15</italic>
###xml 128 136 128 136 <italic>DRB1*15-</italic>
###xml 234 241 234 241 <xref rid="tbl1" ref-type="table">Table 1</xref>
To eliminate the possible confounding effect of linkage disequilibrium (LD) with HLA-DRB1*15, we performed the same analysis in DRB1*15-negative individuals. The OR values for the three tested markers remained substantially the same (Table 1).
###end p 11
###begin p 12
###xml 118 125 118 125 <xref rid="tbl2" ref-type="table">Table 2</xref>
###xml 128 135 128 135 <italic>DRB1*15</italic>
###xml 298 302 298 302 <italic>A*02</italic>
###xml 545 553 545 553 <italic>MOG-142L</italic>
###xml 586 590 586 590 <italic>A*02</italic>
###xml 635 640 635 640 <italic>Cw*05</italic>
###xml 676 683 676 683 <italic>DRB1*15</italic>
###xml 811 819 811 819 <italic>MOG-142L</italic>
###xml 843 851 843 851 <italic>HLA-A*02</italic>
###xml 907 915 907 915 <italic>HLA-A*02</italic>
###xml 917 925 917 925 <italic>MOG-142L</italic>
###xml 973 977 973 977 <italic>A*02</italic>
###xml 1014 1015 1014 1015 <italic>P</italic>
###xml 1032 1036 1032 1036 <italic>A*02</italic>
###xml 1074 1075 1074 1075 <italic>P</italic>
###xml 1130 1131 1130 1131 <italic>D</italic>
###xml 1139 1140 1139 1140 <italic>r</italic>
###xml 1140 1141 1140 1141 <sup>2</sup>
###xml 1225 1232 1225 1232 <xref rid="tbl3" ref-type="table">Table 3</xref>
###xml 1205 1212 <span type="species:ncbi:9606">patient</span>
The relative effect of the three tested HLA-class I markers on MS risk was evaluated by logistic regression analysis (Table 2). DRB1*15 was also included in the model. All individuals were categorized according to the presence or absence of each of the four considered alleles. The OR conferred by A*02 remained similar after accounting for each of the other markers included in the model and for all the markers together, showing that the protective effect was independent of any other analyzed HLA marker. Conversely, the protective effect of MOG-142L was abolished by adjustment for A*02. The lack of a significant association with Cw*05 and the significant risk effect of DRB1*15 were similar with and without the adjustment for the remaining markers. This analysis clearly showed that the association with MOG-142L was not independent of HLA-A*02. This was also indicated by an analysis stratified for HLA-A*02: MOG-142L was not significantly associated either in the A*02 positive (OR=0.96 95% CI=0.74-1.23, P=0.76) or in the A*02 negative (OR=0.80, 95% CI=0.60-1.07, P=0.13). These results were explained by the strong LD (D'=0.59; r2=0.5) between the two alleles both in the control and in the MS patient population (Table 3).
###end p 12
###begin p 13
###xml 42 46 42 46 <italic>A*02</italic>
###xml 51 56 51 56 <italic>Cw*05</italic>
###xml 84 91 84 91 <xref rid="tbl3" ref-type="table">Table 3</xref>
###xml 226 230 226 230 <italic>A*02</italic>
###xml 233 238 233 238 <italic>Cw*05</italic>
###xml 319 326 319 326 <xref rid="tbl4" ref-type="table">Table 4</xref>
###xml 418 422 418 422 <italic>A*02</italic>
###xml 427 432 427 432 <italic>Cw*05</italic>
###xml 453 460 453 460 <xref rid="tbl4" ref-type="table">Table 4</xref>
###xml 484 488 484 488 <italic>A*02</italic>
###xml 491 496 491 496 <italic>Cw*05</italic>
###xml 603 607 603 607 <italic>A*02</italic>
###xml 626 631 626 631 <italic>Cw*05</italic>
###xml 663 671 663 671 <italic>HLA-A*02</italic>
###xml 673 678 673 678 <italic>Cw*05</italic>
###xml 789 797 789 797 <italic>DRB1*15-</italic>
###xml 819 826 819 826 <xref rid="tbl4" ref-type="table">Table 4</xref>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 273 280 <span type="species:ncbi:9606">patient</span>
Considerable LD was also detected between A*02 and Cw*05 in the control population (Table 3). Notably, it was completely absent in the MS patients. This difference was explained by the significantly decreased frequency of the A*02+, Cw*05+ phenotypic combination in the MS patient as opposed to the control population (Table 4). When analyzing in more detail the effect of the different phenotypic combinations of the A*02 and Cw*05 alleles on MS risk (Table 4), it appeared that the A*02+, Cw*05+ combination conferred an OR (0.38) significantly lower than that (OR=0.73) consequent to the presence of A*02 in the absence of Cw*05. Conversely, in the absence of HLA-A*02, Cw*05 showed a significant positive association with MS (OR=1.85). The same results were seen when considering only DRB1*15-negative individuals (Table 4).
###end p 13
###begin p 14
###xml 23 32 23 32 <italic>HLA-Cw*05</italic>
###xml 92 96 92 96 <italic>A*02</italic>
###xml 103 109 103 109 <italic>Cw*05-</italic>
###xml 162 168 162 168 <italic>Cw*05-</italic>
###xml 239 243 239 243 <italic>A*02</italic>
###xml 245 250 245 250 <italic>Cw*05</italic>
###xml 288 293 288 293 <italic>A*02-</italic>
###xml 369 374 369 374 <italic>A*02-</italic>
###xml 620 621 620 621 <italic>P</italic>
###xml 630 632 630 632 <sup>&#8722;5</sup>
###xml 650 659 650 659 <italic>HLA-Cw*05</italic>
###xml 664 668 664 668 <italic>A*02</italic>
###xml 738 743 738 743 <italic>crude</italic>
###xml 748 756 748 756 <italic>adjusted</italic>
###xml 762 769 762 769 <xref rid="tbl2" ref-type="table">Table 2</xref>
Stratification for the HLA-Cw*05 revealed a substantial difference in risk conferred by the A*02 among Cw*05-positive individuals (OR=0.22, 95% CI=0.13-0.38) and Cw*05-negative individuals (OR=0.69, 95% CI=0.58-0.83). When stratifying for A*02, Cw*05 behaved as a protective factor among A*02-positive individuals (OR=0.50, 95% CI=0.33-0.74) and as a risk factor among A*02-negative individuals (OR=1.53, 95% CI=1.04-2.24). The likelihood ratio test used to compare the full model (including the two markers and the interaction term) to the additive model (including only the two markers) was statistically significant (P=4.9 x 10-5). Thus, although HLA-Cw*05 and A*02 are not reciprocally confounders, as there was no difference between crude and adjusted ORs (Table 2), the stratification analysis showed a significant multiplicative interaction between the two markers.
###end p 14
###begin p 15
###xml 97 101 97 101 <italic>A*02</italic>
###xml 104 109 104 109 <italic>Cw*05</italic>
###xml 150 153 150 153 <italic>cis</italic>
###xml 160 165 160 165 <italic>trans</italic>
###xml 333 337 333 337 <italic>A*02</italic>
###xml 342 347 342 347 <italic>Cw*05</italic>
###xml 402 403 402 403 <italic>P</italic>
###xml 421 425 421 425 <italic>A*02</italic>
###xml 428 433 428 433 <italic>Cw*05</italic>
###xml 504 509 504 509 <italic>A*02-</italic>
###xml 579 583 579 583 <italic>A*02</italic>
###xml 671 677 671 677 <italic>A*0201</italic>
###xml 700 704 700 704 <italic>A*02</italic>
###xml 730 736 730 736 <italic>A*0205</italic>
###xml 746 752 746 752 <italic>A*0217</italic>
###xml 759 765 759 765 <italic>A*0201</italic>
###xml 791 795 791 795 <italic>A*02</italic>
###xml 815 819 815 819 <italic>A*02</italic>
###xml 822 827 822 827 <italic>Cw*05</italic>
###xml 840 844 840 844 <italic>A*02</italic>
###xml 847 852 847 852 <italic>Cw*05</italic>
###xml 889 893 889 893 <italic>A*02</italic>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 438 445 <span type="species:ncbi:9606">patient</span>
From the analysis in the case-control population, it was not possible to distinguish whether the A*02+, Cw*05+ individuals carried the two alleles in cis or in trans. We, therefore, analyzed the transmission of these two alleles in 201 family trios. No Mendelian errors were observed. Notably, out of 10 haplotypes that carried both A*02 and Cw*05, none were transmitted to the MS patients (T:NT=0:10; P=0.002). The only A*02+, Cw*05+ MS patient present in this panel inherited the two alleles in trans. A*02-positive individuals of the family trios were sequenced to define the A*02 alleles at a higher resolution. In agreement with the literature (), in these samples, A*0201 was the most frequent A*02 allele (90%) followed by A*0205 (8%) and A*0217 (2%). A*0201 was the most represented A*02 allele both in the A*02+, Cw*05+ and in the A*02+, Cw*05- haplotypes. The same proportion of A*02 subtypes was seen among transmitted and non-transmitted haplotypes (data not shown).
###end p 15
###begin p 16
###xml 29 33 29 33 <italic>A*02</italic>
###xml 35 40 35 40 <italic>Cw*05</italic>
###xml 56 63 56 63 <italic>DRB1*15</italic>
###xml 99 107 99 107 <xref ref-type="fig" rid="fig1">Figure 1</xref>
###xml 207 211 207 211 <italic>A*02</italic>
###xml 214 219 214 219 <italic>Cw*05</italic>
###xml 222 229 222 229 <italic>DRB1*15</italic>
###xml 446 453 446 453 <italic>DRB1*15</italic>
###xml 494 498 494 498 <italic>A*02</italic>
###xml 501 506 501 506 <italic>Cw*05</italic>
###xml 541 545 541 545 <italic>A*02</italic>
###xml 554 559 554 559 <italic>Cw*05</italic>
###xml 644 648 644 648 <italic>A*02</italic>
###xml 653 658 653 658 <italic>Cw*05</italic>
###xml 664 671 664 671 <italic>DRB1*15</italic>
###xml 812 813 812 813 <italic>N</italic>
###xml 864 871 864 871 <italic>DRB1*15</italic>
###xml 949 953 949 953 <italic>A*02</italic>
###xml 972 977 972 977 <italic>Cw*05</italic>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
The joint effect of class I (A*02, Cw*05) and class II (DRB1*15) markers on MS risk is reported in Figure 1. All the combinations of these three alleles showed a significantly increased risk relative to the A*02+, Cw*05+, DRB1*15- phenotype, which is characterized both by the presence of the class I markers conferring the highest protection and by the absence of the class II allele conferring the highest risk. The three combinations carrying DRB1*15 in the absence of the highly protective A*02+, Cw*05+ phenotype (that is carrying only A*02 or only Cw*05 or none of them) showed a similar eightfold increased risk. In the presence of both A*02 and Cw*05, the DRB1*15 risk approximately halved to 4.57, although this difference was not statistically significant owing to the low frequency of this phenotype (N=13 MS patients and 8 controls). In the absence of DRB1*15, a differently increased risk was observed according to the presence of only A*02 (OR=2.11) or only Cw*05 (OR=5.47) or none of them (OR=3.14).
###end p 16
###begin title 17
Stratification for DRB1 alleles
###end title 17
###begin p 18
###xml 69 73 69 73 <italic>DRB1</italic>
###xml 97 104 97 104 <italic>DRB1*15</italic>
###xml 139 147 139 147 <italic>HLA-A*02</italic>
###xml 149 154 149 154 <italic>Cw*05</italic>
###xml 187 191 187 191 <italic>DRB1</italic>
###xml 266 270 266 270 <italic>DRB1</italic>
###xml 308 315 308 315 <italic>DRB1*15</italic>
###xml 377 378 377 378 <italic>P</italic>
###xml 387 390 387 390 <sup>&#8722;14</sup>
###xml 410 418 410 418 <italic>DRB1*15-</italic>
###xml 504 511 504 511 <italic>DRB1*04</italic>
###xml 540 541 540 541 <italic>P</italic>
###xml 550 552 550 552 <sup>&#8722;4</sup>
###xml 586 593 586 593 <italic>DRB1*07</italic>
###xml 649 650 649 650 <italic>P</italic>
###xml 691 698 691 698 <italic>DRB1*03</italic>
###xml 786 794 786 794 <italic>HLA-A*02</italic>
###xml 799 803 799 803 <italic>DRB1</italic>
###xml 812 813 812 813 <italic>D</italic>
###xml 831 832 831 832 <italic>V</italic>
###xml 852 861 852 861 <italic>HLA-Cw*05</italic>
###xml 866 870 866 870 <italic>DRB1</italic>
###xml 879 880 879 880 <italic>D</italic>
###xml 898 899 898 899 <italic>V</italic>
###xml 929 933 929 933 <italic>A*02</italic>
###xml 981 985 981 985 <italic>DRB1</italic>
###xml 1032 1033 1032 1033 <italic>P</italic>
###xml 1042 1044 1042 1044 <sup>&#8722;5</sup>
###xml 1058 1059 1058 1059 <italic>P</italic>
###xml 1068 1070 1068 1070 <sup>&#8722;4</sup>
###xml 1112 1116 1112 1116 <italic>DRB1</italic>
###xml 1118 1123 1118 1123 <italic>Cw*05</italic>
###xml 1172 1173 1172 1173 <italic>P</italic>
###xml 1192 1193 1192 1193 <italic>P</italic>
###xml 1221 1229 1221 1229 <italic>HLA-A*02</italic>
###xml 1287 1291 1287 1291 <italic>DRB1</italic>
###xml 1341 1346 1341 1346 <italic>Cw*05</italic>
###xml 1403 1407 1403 1407 <italic>DRB1</italic>
###xml 1445 1452 1445 1452 <italic>DRB1*03</italic>
###xml 1521 1530 1521 1530 <italic>HLA-Cw*05</italic>
###xml 1553 1561 1553 1561 <italic>DRB1*03-</italic>
###xml 1610 1611 1610 1611 <italic>P</italic>
###xml 1672 1676 1672 1676 <italic>A*02</italic>
###xml 1678 1683 1678 1683 <italic>Cw*05</italic>
###xml 1762 1766 1762 1766 <italic>DRB1</italic>
###xml 1814 1821 1814 1821 <italic>DRB1*03</italic>
###xml 1823 1830 1823 1830 <xref rid="tbl5" ref-type="table">Table 5</xref>
###xml 1852 1856 1852 1856 <italic>A*02</italic>
###xml 1867 1872 1867 1872 <italic>Cw*05</italic>
###xml 1928 1936 1928 1936 <italic>DRB1*03-</italic>
###xml 2026 2034 2026 2034 <italic>DRB1*03-</italic>
###xml 2070 2074 2070 2074 <italic>A*02</italic>
###xml 2085 2090 2085 2090 <italic>Cw*05</italic>
###xml 2154 2161 2154 2161 <italic>DRB1*03</italic>
###xml 2239 2244 2239 2244 <italic>Cw*05</italic>
###xml 2294 2298 2294 2298 <italic>A*02</italic>
###xml 2317 2321 2317 2321 <italic>DRB1</italic>
###xml 2349 2353 2349 2353 <italic>A*02</italic>
###xml 2403 2410 2403 2410 <italic>DRB1*03</italic>
###xml 2412 2419 2412 2419 <xref rid="tbl5" ref-type="table">Table 5</xref>
To test whether the detected associations were consequent on LD with DRB1 alleles different from DRB1*15, we evaluated the relationship of HLA-A*02, Cw*05 and their combinations with the DRB1 locus in a random subset of 562 MS cases and 888 controls fully typed for DRB1 at low resolution. In this subgroup, DRB1*15 was positively MS associated with OR=2.86 (95% CI=2.14-3.83; P=8.4 x 10-14). When considering DRB1*15-negative individuals, there was an additional significantly positive association with DRB1*04 (OR=1.88, 95% CI=1.34-2.63, P=1.6 x 10-4) and a negative association with DRB1*07 of borderline significance (OR=0.69, 95% CI=0.49-0.98, P=0.036). At variance with other studies, DRB1*03 was not associated (OR=1.0, 95% CI=0.72-1.39). A modest global LD was detected between HLA-A*02 and DRB1 (Global D'=0.149, Cramer's V=0.176) and between HLA-Cw*05 and DRB1 (Global D'=0.280, Cramer's V=0.194). The association with A*02 remained significant after conditioning on the DRB1 locus by the COCAPHASE program (unconditioned P=1.9 x 10-5; conditioned P=2.2 x 10-4), thus showing that it is independent of DRB1. Cw*05 was not significantly associated (unconditioned P=0.09; conditioned P=0.19). The OR conferred by HLA-A*02 did not substantially change after conditioning for each DRB1 allele separately (data not shown). In addition, Cw*05 showed very similar results after conditioning for each DRB1 allele with the notable exception of DRB1*03: a protective effect with borderline significance was evidenced for HLA-Cw*05 when considering only DRB1*03-negative individuals (OR=0.58, 95% CI=0.36-0.92; P=0.02). When the same procedure was applied to the different A*02, Cw*05 combinations, there was no substantial difference after conditioning for each DRB1 allele separately, again with the exception of DRB1*03 (Table 5). Interestingly, the A*02 negative, Cw*05 positive combination was significantly increased among DRB1*03-positive individuals (OR=3.89), whereas it was not significantly associated with MS among DRB1*03-negative individuals (OR=0.96). The A*02 positive, Cw*05 positive combination remained significantly protective both in DRB1*03 positive (OR=0.28) and negative (OR=0.39) individuals. Thus, the presence of Cw*05 was significantly protective in combination with A*02, independently of DRB1, whereas in the absence of A*02, it behaved as a risk marker in combination with DRB1*03 (Table 5).
###end p 18
###begin title 19
Discussion
###end title 19
###begin p 20
###xml 149 157 149 157 <italic>HLA-A*02</italic>
###xml 158 159 158 159 <xref ref-type="other" rid="bib9">9</xref>
###xml 161 163 161 163 <xref ref-type="other" rid="bib13">13</xref>
###xml 158 163 158 163 <sup><xref ref-type="other" rid="bib9">9</xref>, <xref ref-type="other" rid="bib13">13</xref></sup>
###xml 163 172 163 172 <italic>HLA-Cw*05</italic>
###xml 172 174 172 174 <xref ref-type="other" rid="bib11">11</xref>
###xml 172 174 172 174 <sup><xref ref-type="other" rid="bib11">11</xref></sup>
###xml 179 187 179 187 <italic>MOG-142L</italic>
###xml 188 190 188 190 <xref ref-type="other" rid="bib12">12</xref>
###xml 188 190 188 190 <sup><xref ref-type="other" rid="bib12">12</xref></sup>
This work stems from previous studies undertaken by our group and others, each reporting an MS association with distinct HLA-class I markers, namely HLA-A*02,9, 13HLA-Cw*0511 and MOG-142L.12 We here analyze the relationship among these three markers for MS susceptibility.
###end p 20
###begin p 21
###xml 43 51 43 51 <italic>HLA-A*02</italic>
###xml 78 85 78 85 <italic>DRB1*15</italic>
###xml 110 114 110 114 <italic>DRB1</italic>
###xml 284 285 284 285 <xref ref-type="other" rid="bib9">9</xref>
###xml 284 285 284 285 <sup><xref ref-type="other" rid="bib9">9</xref></sup>
###xml 298 300 298 300 <xref ref-type="other" rid="bib13">13</xref>
###xml 298 300 298 300 <sup><xref ref-type="other" rid="bib13">13</xref></sup>
###xml 475 481 475 481 <italic>et al.</italic>
###xml 481 482 481 482 <xref ref-type="other" rid="bib7">7</xref>
###xml 481 482 481 482 <sup><xref ref-type="other" rid="bib7">7</xref></sup>
###xml 534 542 534 542 <italic>HLA-A*02</italic>
###xml 606 611 606 611 <italic>HLA-A</italic>
###xml 663 667 663 667 <italic>HLA-</italic>
###xml 714 715 714 715 <xref ref-type="other" rid="bib8">8</xref>
###xml 714 715 714 715 <sup><xref ref-type="other" rid="bib8">8</xref></sup>
###xml 955 956 955 956 <xref ref-type="other" rid="bib9">9</xref>
###xml 958 960 958 960 <xref ref-type="other" rid="bib13">13</xref>
###xml 955 960 955 960 <sup><xref ref-type="other" rid="bib9">9</xref>, <xref ref-type="other" rid="bib13">13</xref></sup>
###xml 987 995 987 995 <italic>HLA-A*02</italic>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
We confirmed a strong protective effect of HLA-A*02, which was independent of DRB1*15 as well as of any other DRB1 allele. This association has now been detected, with similar ORs, in three populations with a different genetic background, respectively, from Italy (this paper), Sweden9 and Tasmania13 based on a total of over 2600 MS patients and 2700 controls. These data concur to demonstrate a role in MS of this allele (or of a variation in LD with it). Conversely, Chao et al.7 failed to observe a transmission distortion of the HLA-A*02 allele in a large family sample from Canada and no SNPs in the HLA-A region showed association with MS independently of HLA-class II loci in Canadian and Finnish families.8 As both these studies were based on an intrafamilial association method, an obvious explanation of the discrepancy could be a stratification problem related to the case-control approach used in the present as well as the other two studies.9, 13 However, as a significant HLA-A*02 association was seen in independent studies and in three different populations, this simple explanation seems unlikely and further studies are needed to address this point.
###end p 21
###begin p 22
###xml 4 12 4 12 <italic>HLA-A*02</italic>
###xml 139 147 139 147 <italic>MOG-142L</italic>
###xml 202 210 202 210 <italic>HLA-A*02</italic>
###xml 256 261 256 261 <italic>V142L</italic>
###xml 279 282 279 282 <italic>MOG</italic>
###xml 370 376 370 376 <italic>et al.</italic>
###xml 376 378 376 378 <xref ref-type="other" rid="bib12">12</xref>
###xml 376 378 376 378 <sup><xref ref-type="other" rid="bib12">12</xref></sup>
The HLA-A*02 protection remained similar after accounting for the other two analyzed class I markers. Conversely, the protective effect of MOG-142L was secondary to its high linkage disequilibrium with HLA-A*02. This excluded a direct role of the missense V142L variation in the MOG gene, a previously suggested strong MS susceptibility candidate (reviewed in D'Alfonso et al.12).
###end p 22
###begin p 23
###xml 15 20 15 20 <italic>Cw*05</italic>
###xml 81 89 81 89 <italic>DRB1*15-</italic>
###xml 168 172 168 172 <italic>DRB1</italic>
###xml 182 187 182 187 <italic>Cw*05</italic>
###xml 274 281 274 281 <italic>DRB1*03</italic>
###xml 339 345 339 345 <italic>et al.</italic>
###xml 345 347 345 347 <xref ref-type="other" rid="bib11">11</xref>
###xml 345 347 345 347 <sup><xref ref-type="other" rid="bib11">11</xref></sup>
###xml 384 389 384 389 <italic>Cw*05</italic>
###xml 449 456 449 456 <italic>DRB1*03</italic>
###xml 481 485 481 485 <italic>DRB1</italic>
###xml 495 502 495 502 <italic>DRB1*15</italic>
###xml 504 513 504 513 <italic>DRB1*0103</italic>
###xml 531 539 531 539 <italic>DRB1*03-</italic>
###xml 583 587 583 587 <italic>A*02</italic>
###xml 589 594 589 594 <italic>Cw*05</italic>
###xml 645 652 645 652 <italic>DRB1*15</italic>
###xml 663 664 663 664 <italic>P</italic>
###xml 684 689 684 689 <italic>Cw*05</italic>
###xml 738 746 738 746 <italic>HLA-A*02</italic>
###xml 768 772 768 772 <italic>A*02</italic>
###xml 779 785 779 785 <italic>Cw*05-</italic>
###xml 867 873 867 873 <italic>Cw*05-</italic>
###xml 938 943 938 943 <italic>Cw*05</italic>
###xml 1023 1032 1023 1032 <italic>HLA-A*02-</italic>
###xml 1082 1092 1082 1092 <italic>Cw*05-A*02</italic>
###xml 1140 1147 1140 1147 <italic>DRB1*03</italic>
###xml 1149 1156 1149 1156 <xref rid="tbl5" ref-type="table">Table 5</xref>
In this study, Cw*05 was not associated with MS either in the whole sample or in DRB1*15-negative individuals. However, when stratifying the results separately for all DRB1 alleles, Cw*05 conferred a significant protection for MS in the subgroup of individuals negative for DRB1*03. This is partially in line with the data reported by Yeo et al.11 who observed a protective effect of Cw*05 in the whole sample as well as in individuals negative for DRB1*03 and other MS-associated DRB1 alleles (DRB1*15, DRB1*0103). Conversely, in DRB1*03-positive individuals, and in the absence of A*02, Cw*05 was a risk marker and conferred a risk similar to DRB1*15 (OR=3.89, P=0.0006). Moreover, Cw*05 significantly enhanced the protection effect of HLA-A*02: the OR conferred by A*02 among Cw*05-positive individuals (OR=0.22, 95% CI=0.13-0.38) was about 1/3 smaller than among Cw*05-negative individuals (OR=0.69, 95% CI=0.58-0.83). Thus, although Cw*05 itself was not significantly associated to MS, it behaved as a modifier of the HLA-A*02-mediated protection. The protective effect of the Cw*05-A*02 combination was independent of the presence of DRB1*03 (Table 5).
###end p 23
###begin p 24
###xml 43 48 43 48 <italic>Cw*05</italic>
###xml 101 106 101 106 <italic>Cw*05</italic>
###xml 175 177 175 177 <xref ref-type="other" rid="bib14">14</xref>
###xml 179 181 179 181 <xref ref-type="other" rid="bib15">15</xref>
###xml 183 185 183 185 <xref ref-type="other" rid="bib16">16</xref>
###xml 175 185 175 185 <sup><xref ref-type="other" rid="bib14">14</xref>, <xref ref-type="other" rid="bib15">15</xref>, <xref ref-type="other" rid="bib16">16</xref></sup>
###xml 207 214 207 214 <italic>DRB1*03</italic>
###xml 235 239 235 239 <italic>A*02</italic>
###xml 254 258 254 258 <italic>A*30</italic>
###xml 260 265 260 265 <italic>Cw*05</italic>
###xml 267 271 267 271 <italic>B*18</italic>
###xml 273 280 273 280 <italic>DRB1*03</italic>
###xml 307 311 307 311 <italic>A*02</italic>
###xml 321 328 321 328 <italic>DRB1*03</italic>
###xml 343 349 343 349 <italic>A*0201</italic>
###xml 351 358 351 358 <italic>Cw*0501</italic>
###xml 360 366 360 366 <italic>B*4402</italic>
###xml 368 377 368 377 <italic>DRB1*0401</italic>
###xml 389 395 389 395 <italic>A*0201</italic>
###xml 397 404 397 404 <italic>Cw*0501</italic>
###xml 406 412 406 412 <italic>B*1801</italic>
###xml 414 423 414 423 <italic>DRB1*1102</italic>
These data suggest that the association of Cw*05 with MS varies according to its haplotypic context. Cw*05 is a marker of three ancestral or conserved extended HLA haplotypes,14, 15, 16 one of which carries DRB1*03 and is negative for A*02, namely 18.2 [A*30, Cw*05, B*18, DRB1*03], and the other two carry A*02, but not DRB1*03, namely 44.1 [A*0201, Cw*0501, B*4402, DRB1*0401] and 18.3 [A*0201, Cw*0501, B*1801, DRB1*1102].
###end p 24
###begin p 25
###xml 244 252 244 252 <italic>DRB1*03-</italic>
###xml 288 312 288 312 <italic>A1, Cw*07, B*08, DRB1*03</italic>
###xml 366 370 366 370 <italic>A*02</italic>
###xml 373 378 373 378 <italic>Cw*05</italic>
###xml 381 389 381 389 <italic>DRB1*03+</italic>
###xml 547 554 547 554 <italic>DRB1*03</italic>
###xml 625 632 625 632 <italic>DRB1*03</italic>
The 18.2 HLA-extended haplotype is typical of the Sardinian population and, to a lesser extent, of other Mediterranean populations. Conversely, in the populations of northern European origin, this DR3 haplotype is very rare and the majority of DRB1*03-positive individuals carry the 8.1 [A1, Cw*07, B*08, DRB1*03] extended haplotype. The positive association of the A*02-, Cw*05+, DRB1*03+ combination observed in this study may reflect the effect of the 18.2 haplotype. It is tempting to speculate that the strong positive association of MS with DRB1*03 observed in Sardinia is related to the 18.2 haplotype and not only to DRB1*03 itself.
###end p 25
###begin p 26
###xml 21 31 21 31 <italic>A*02-Cw*05</italic>
###xml 297 307 297 307 <italic>A*02-Cw*05</italic>
###xml 460 464 460 464 <italic>A*02</italic>
###xml 469 474 469 474 <italic>Cw*05</italic>
As stated above, the A*02-Cw*05 combination is carried by two HLA ancestral haplotypes (44.1 and 18.3). However, as the individuals included in this study were not typed for HLA-B and other HLA markers, from our data it is not possible to conclude whether the enhanced MS-protective effect of the A*02-Cw*05 combination is due to an haplotype effect (that is the presence of a primarily associated protective factor carried by the extended haplotype marked by A*02 and Cw*05) or to a direct interactive role of the two markers.
###end p 26
###begin p 27
###xml 64 69 64 69 <italic>Cw*05</italic>
###xml 115 119 115 119 <italic>A*02</italic>
###xml 131 136 131 136 <italic>Cw*05</italic>
###xml 174 179 174 179 <italic>A*02-</italic>
###xml 255 260 255 260 <italic>A*02-</italic>
###xml 371 375 371 375 <italic>A*02</italic>
###xml 380 385 380 385 <italic>Cw*05</italic>
###xml 440 441 440 441 <italic>P</italic>
###xml 459 463 459 463 <italic>A*02</italic>
###xml 466 471 466 471 <italic>Cw*05</italic>
###xml 560 564 560 564 <italic>A*02</italic>
###xml 566 570 566 570 <italic>B*44</italic>
###xml 575 580 575 580 <italic>Cw*05</italic>
###xml 683 689 683 689 <italic>et al.</italic>
###xml 689 691 689 691 <xref ref-type="other" rid="bib11">11</xref>
###xml 689 691 689 691 <sup><xref ref-type="other" rid="bib11">11</xref></sup>
###xml 726 741 726 741 <italic>A*02-B*44-Cw*05</italic>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 476 483 <span type="species:ncbi:9606">patient</span>
The evidence in favor of an haplotype effect is as follows: (i) Cw*05 was not associated with MS in the absence of A*02. Actually, Cw*05 behaved as a protective factor among A*02-positive individuals (OR=0.50, 95% CI 0.33-0.74) and as a risk factor among A*02-negative individuals (OR=1.53, 95% CI 1.04-2.24). (ii) In family trios, out of 10 haplotypes that carried both A*02 and Cw*05, none were transmitted to the MS patients (T:NT=0:10; P=0.002). The only A*02+, Cw*05+ MS patient present in this panel inherited the two alleles in trans. (iii) Each of the A*02, B*44 and Cw*05 alleles (characterizing the 44.1 ancestral haplotype) was significantly decreased in the study of Yeo et al.11 However, the association with the A*02-B*44-Cw*05 haplotypic combination was not investigated by the authors.
###end p 27
###begin p 28
###xml 110 112 110 112 <xref ref-type="other" rid="bib17">17</xref>
###xml 110 112 110 112 <sup><xref ref-type="other" rid="bib17">17</xref></sup>
###xml 140 144 140 144 <italic>A*02</italic>
###xml 161 162 161 162 <sup>*</sup>
###xml 219 220 219 220 <sup>*</sup>
###xml 233 234 233 234 <italic>P</italic>
###xml 237 239 237 239 <sup>&#8722;4</sup>
###xml 262 263 262 263 <sup>*</sup>
###xml 309 315 309 315 <italic>et al.</italic>
###xml 315 317 315 317 <xref ref-type="other" rid="bib17">17</xref>
###xml 315 317 315 317 <sup><xref ref-type="other" rid="bib17">17</xref></sup>
###xml 442 443 442 443 <sup>*</sup>
###xml 549 559 549 559 <italic>HLA-A*0201</italic>
###xml 578 579 578 579 <sup>*</sup>
###xml 817 819 817 819 <xref ref-type="other" rid="bib17">17</xref>
###xml 817 819 817 819 <sup><xref ref-type="other" rid="bib17">17</xref></sup>
###xml 381 396 <span type="species:ncbi:10090">transgenic mice</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 453 458 <span type="species:ncbi:9606">human</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
On the other hand, evidence reported in this study and from work undertaken using an experimental animal model17 points to a direct role of A*02. In our study, A*02 was also significantly protective in the absence of Cw*05 (OR=0.73, P<10-4). Thus, an effect of A*02 alone cannot be excluded. Moreover, Friese et al.17 recently reported that the MS-like disease developed by double transgenic mice expressing both a human HLA-class I allele (A*03) and a human myelin-specific autoreactive T-cell receptor is completely prevented by further adding an HLA-A*0201 transgene. Thus, A*02, which protects against MS in human populations, also prevents an MS-like disease in transgenic humanized mice. This protection resulted from thymic deletion of autoreactive T cells, which greatly reduced their number in the periphery.17
###end p 28
###begin p 29
###xml 5 10 5 10 <italic>HLA-A</italic>
###xml 15 17 15 17 <italic>-C</italic>
###xml 174 176 174 176 <xref ref-type="other" rid="bib18">18</xref>
###xml 178 180 178 180 <xref ref-type="other" rid="bib19">19</xref>
###xml 174 180 174 180 <sup><xref ref-type="other" rid="bib18">18</xref>, <xref ref-type="other" rid="bib19">19</xref></sup>
###xml 489 491 489 491 <xref ref-type="other" rid="bib20">20</xref>
###xml 489 491 489 491 <sup><xref ref-type="other" rid="bib20">20</xref></sup>
###xml 543 545 543 545 <xref ref-type="other" rid="bib21">21</xref>
###xml 543 545 543 545 <sup><xref ref-type="other" rid="bib21">21</xref></sup>
###xml 696 697 696 697 <sup>*</sup>
###xml 943 945 943 945 <xref ref-type="other" rid="bib21">21</xref>
###xml 943 945 943 945 <sup><xref ref-type="other" rid="bib21">21</xref></sup>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
Both HLA-A and -C genes are interesting candidates for a direct role in MS pathogenesis, as their encoded molecules present antigenic peptides and interact with NK receptors.18, 19 However, several other genes in this region might be primarily associated with MS. The 1.3 Mb interval within HLA-A and -C genes contains 46 genes (24% of which encoding molecules involved in immune functions) and about 4000 SNPs, according to the recently reported sequence of eight HLA ancestral haplotypes20 and HapMap data (). A genome-wide association study21 in about 1000 US MS patients and 1000 matched controls identified several MS-associated SNPs in the HLA-class I region after conditioning for HLA-DRB1*15. Among these, the top signals were localized around members of the tripartite motif (TRIM) gene family, mapping about 200 kb centromeric to HLA-A. Although their function is unknown, the presence of a RING domain suggests DNA-binding activity.21
###end p 29
###begin p 30
###xml 223 225 223 225 <xref ref-type="other" rid="bib22">22</xref>
###xml 227 229 227 229 <xref ref-type="other" rid="bib23">23</xref>
###xml 231 233 231 233 <xref ref-type="other" rid="bib24">24</xref>
###xml 223 233 223 233 <sup><xref ref-type="other" rid="bib22">22</xref>, <xref ref-type="other" rid="bib23">23</xref>, <xref ref-type="other" rid="bib24">24</xref></sup>
###xml 346 347 346 347 <sup>*</sup>
###xml 425 426 425 426 <sup>*</sup>
###xml 530 531 530 531 <sup>*</sup>
###xml 540 541 540 541 <sup>*</sup>
###xml 545 553 545 553 <xref ref-type="fig" rid="fig1">Figure 1</xref>
###xml 579 580 579 580 <sup>*</sup>
###xml 585 586 585 586 <sup>*</sup>
In conclusion, this study provides additional supportive evidence indicating that the HLA-class I region does indeed exert an additional influence on the risk of MS, analogous to that reported for other autoimmune diseases.22, 23, 24 Moreover, it identifies haplospecific markers conferring a high MS protection. Notably, although in general DRB1*15-negative individuals have an about threefold lower MS risk relative to DRB1*15-positive individuals, their risk was significantly decreased (about eightfold) if they also carried A*02 and Cw*05 (Figure 1). The highly protective A*02-Cw*05 combination is rare (0.078 phenotypic frequency in our controls, 0.025 haplotype frequency in our family trios) and, therefore, unless it tags a primary factor with higher frequency, it confers a modest modification of the HLA attributable MS risk in the population. In any case, the identification of the mechanism mediating the protective effect might throw new light on MS pathogenesis.
###end p 30
###begin title 31
Materials and methods
###end title 31
###begin title 32
Subjects
###end title 32
###begin p 33
###xml 92 98 92 98 <italic>et al.</italic>
###xml 99 101 99 101 <xref ref-type="other" rid="bib25">25</xref>
###xml 99 101 99 101 <sup><xref ref-type="other" rid="bib25">25</xref></sup>
###xml 188 189 188 189 <sup>*</sup>
###xml 656 658 650 652 <xref ref-type="other" rid="bib26">26</xref>
###xml 656 658 650 652 <sup><xref ref-type="other" rid="bib26">26</xref></sup>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 662 670 <span type="species:ncbi:9606">patients</span>
###xml 797 805 <span type="species:ncbi:9606">patients</span>
A total of 1273 Italian MS patients (female:male ratio 2:1) diagnosed according to McDonald et al.,25 were genotyped for the three HLA-class I markers considered in this study and for DRB1*15. For 201 of these, a DNA sample of the parents was also available (family trios). The mean age of the MS patients at disease onset was 31+/-10.16 years, the mean age at time of analysis was 40+/-15.52 years and the mean disease duration was 12+/-9.31 years. Eighty-four percent of the patients were affected by the relapsing remitting, 7% by the secondary progressive and 9% by the primary progressive form of the disease, defined according to Lublin and Reingold.26 MS patients with Sardinian ancestors were excluded to avoid the introduction of confounding sources of heterogeneity. Enrolment of the MS patients followed their informed consent. The study was approved by the Ethical Committees of the collaborating clinical centers.
###end p 33
###begin p 34
###xml 180 188 <span type="species:ncbi:9606">patients</span>
Controls included 1075 Italian individuals (medical students, university and hospital staff, blood donors; female:male ratio 1:1.1) matched for age and regional origin with the MS patients and also typed for all considered markers.
###end p 34
###begin p 35
###xml 92 94 92 94 <xref ref-type="other" rid="bib12">12</xref>
###xml 92 94 92 94 <sup><xref ref-type="other" rid="bib12">12</xref></sup>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
MS patients (82%) and controls (30%) in part overlap with those included in a previous paper12 and were selected for inclusion on the basis of the availability of DNA and of HLA genotypes.
###end p 35
###begin title 36
MOG-V142L typing
###end title 36
###begin p 37
The newly included samples were typed using a pre-designed TaqMan SNP Genotyping Assay (probe code: C__25474376_10). Reactions were performed according to the manufacturer's protocol using 25 ng of DNA. The PCR reaction was set up on a 7000 Applied Biosystems instrument. Genotypes were detected using the 7000 System Software (Applied Biosystems, Foster City, CA, USA).
###end p 37
###begin p 38
###xml 111 113 111 113 <xref ref-type="other" rid="bib12">12</xref>
###xml 111 113 111 113 <sup><xref ref-type="other" rid="bib12">12</xref></sup>
A sub-sample of 60 individuals were typed both with this method and with the method used in the previous paper.12 The results were consistent for all tested samples.
###end p 38
###begin title 39
###xml 5 6 5 6 <sup>*</sup>
HLA-A*02 typing
###end title 39
###begin p 40
###xml 0 5 0 5 <italic>HLA-A</italic>
###xml 92 93 92 93 <bold>R</bold>
###xml 291 299 291 299 <italic>HLA-A*02</italic>
###xml 350 358 350 358 <italic>HLA-A*02</italic>
HLA-A exon 2 was amplified using a specific couple of primers (Forward: 5'-CGACGCCGCGAGCCAGARGAT-3', Reverse: 5'-GGCCCGTCCGTGGGGGATGA-3'). The PCR product (213 bp) was digested using the restriction enzyme Kpn2 I. This enzyme recognizes and cuts the rs3173427-T sequence that is specific of HLA-A*02. By this approach, it was possible to distinguish HLA-A*02 homozygotes (displaying two fragments of 159 and 54 bp) from heterozygotes (displaying three fragments of 159, 54 and 213 bp). The digestion was performed at 55 degreesC for 4 h, and then the enzyme was inactivated at 80 degreesC for 20 min.
###end p 40
###begin p 41
###xml 0 9 0 9 <italic>HLA-A*02-</italic>
###xml 107 115 107 115 <italic>HLA-A*02</italic>
###xml 236 237 236 237 <bold>R</bold>
###xml 329 331 328 330 <sup>&#8211;1</sup>
###xml 351 353 349 351 <sup>&#8211;1</sup>
###xml 378 379 376 377 <sc>M</sc>
###xml 384 385 382 383 <sub>2</sub>
HLA-A*02-positive individuals of family trios were also analyzed by sequencing exon 2 and exon 3 to define HLA-A*02 alleles at a higher resolution. Exon 2 and 3 were amplified together in the same fragment (Forward: 5'-CGACGCCGCGAGCCAGARGAT-3', Reverse: 5'-AACGGGAAGGAGACGCTGC-3'). The reaction mix was performed using 0.02 U mul-1 TaqAB, 0.2 pmol mul-1 of every primers, 1.75 mM MgCl2 and glycerol to 7.4%. PCR was made at 60 degreesC annealing temperature for 35 cycles. PCR products were sequenced using nested primers: 5'-GGCCCGTCCGTGGGGGATGA-3' for exon 2 and 5'-TCAGTTTAGGCCAAAAATCC-3' for exon 3. Sequences were analyzed with the automatic sequencer Applied Biosystems (ABI) 3100.
###end p 41
###begin title 42
###xml 6 7 6 7 <sup>*</sup>
HLA-Cw*05 allele-specific PCR
###end title 42
###begin p 43
###xml 31 40 31 40 <italic>HLA-Cw*05</italic>
###xml 142 144 142 144 <xref ref-type="other" rid="bib27">27</xref>
###xml 142 144 142 144 <sup><xref ref-type="other" rid="bib27">27</xref></sup>
###xml 223 224 223 224 <sup>*</sup>
###xml 450 452 449 451 <sup>&#8211;1</sup>
###xml 485 487 483 485 <sup>&#8211;1</sup>
###xml 491 501 489 499 <italic>HLA-Cw*05-</italic>
###xml 532 534 529 531 <sup>&#8211;1</sup>
###xml 570 571 567 568 <sc>M</sc>
###xml 579 580 576 577 <sub>2</sub>
###xml 670 679 667 676 <italic>HLA-Cw*05</italic>
###xml 714 715 711 712 <sup>*</sup>
All the samples were typed for HLA-Cw*05 by an allele-specific PCR after the conditions of the 12th International Histocompatibility Workshop.27 In detail, specific primers pairs were used to amplify in the same tube HLA-Cw*05 (Forward: 5'-CCGAGTGAACCTGCGGAAA-3', Reverse: 5'-CGCGCGCTGCAGCGTCTT-3') and a 796 bp internal control fragment (Forward: 5'-TGCCAAGTGGAGCACCCAA-3', Reverse: 5'-GCATCTTGCTCTGTGCAGAT-3'). The reaction mix contained 0.02 U mul-1 TaqAB (AB Analitica), 1 pmol mul-1 of HLA-Cw*05-specific primers, 0.33 pmol mul-1 of internal control primers and 2 mM of MgCl2. By this approach, it was possible to specifically identify all the samples positive for HLA-Cw*05, but not to distinguish between Cw*05 homozygotes and heterozygotes.
###end p 43
###begin title 44
DRB1 locus analysis
###end title 44
###begin p 45
###xml 61 65 61 65 <italic>DRB1</italic>
###xml 96 100 96 100 <italic>DRB1</italic>
For 562 MS cases and 888 controls, a complete low-resolution DRB1 typing was already available. DRB1 alleles were typed by the DR low-resolution PCR-SSP (Sequence Specific Primer amplification) kit (Dynal or BAG, Formedic, Milan, Italy).
###end p 45
###begin p 46
###xml 59 66 59 66 <italic>DRB1*15</italic>
###xml 331 333 330 332 <sup>&#8211;1</sup>
###xml 374 376 372 374 <sup>&#8211;1</sup>
###xml 381 382 379 380 <sup>*</sup>
###xml 416 418 413 415 <sup>&#8211;1</sup>
###xml 456 457 453 454 <sc>M</sc>
###xml 465 466 462 463 <sub>2</sub>
###xml 560 561 557 558 <sup>*</sup>
###xml 600 601 597 598 <sup>*</sup>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
The remaining MS patients and controls were typed only for DRB1*15 by an allele-specific PCR (Forward primer: 5'-CCTGTGGCAGCCTAAGAGG-3', Reverse primer: 5'-CCGCGCCTGCTCCAGGAT-3') with an internal control fragment (Forward: 5'-TGTTCTGTATTTGTGTTGTCTGATG-3', Reverse: 5'-GTGCTCAGAGAGGCAAGGTT-3'). The reaction mix contained 0.02 U mul-1 TaqAB (Applied Biosystems), 0.5 pmol mul-1 DRB1*15-specific primers, 0.25 pmol mul-1 of internal control primers and 1.5 mM of MgCl2. By this approach, it was possible to specifically identify all the samples positive for DRB1*15, but not to distinguish between DRB1*15 homozygotes and heterozygotes.
###end p 46
###begin title 47
Quality control of allele-specific HLA typing
###end title 47
###begin p 48
###xml 35 36 35 36 <sup>*</sup>
###xml 42 43 42 43 <sup>*</sup>
###xml 54 55 54 55 <sup>*</sup>
###xml 205 207 205 207 <xref ref-type="other" rid="bib27">27</xref>
###xml 205 207 205 207 <sup><xref ref-type="other" rid="bib27">27</xref></sup>
The genotype methods used to type A*02, Cw*05 and DRB1*15 alleles were validated by typing 51 HLA homozygous typing cell lines from the reference panel of the 12th International Histocompatibility Workshop27 and 55 individuals previously typed with a commercial kit.
###end p 48
###begin title 49
Statistical analysis
###end title 49
###begin p 50
###xml 226 227 226 227 <italic>P</italic>
Unconditional logistical regression was carried out to determine the effect of the considered markers on MS susceptibility. The association of each polymorphism with the disease was measured by the OR and its 95% CI. Reported P-values were not corrected for the number of comparisons.
###end p 50
###begin p 51
The potential confounding variables were assessed individually by comparing the log-likelihood ratios derived from a model with and without the variable. This analysis was set up using multivariate models using the four considered markers. All analyses were adjusted for sex. The different models were compared by the likelihood ratio test.
###end p 51
###begin p 52
The interaction (modification) effect was assessed by comparing ORs across levels of potential modifying variables. Inclusion of appropriate interaction terms in the logistic regression model was used to assess the statistical significance of the interactions. For each marker, the potential effect modification by sex variable was also tested.
###end p 52
###begin p 53
###xml 75 77 75 77 <xref ref-type="other" rid="bib28">28</xref>
###xml 75 77 75 77 <sup><xref ref-type="other" rid="bib28">28</xref></sup>
The main-effects test of the COCAPHASE program, part of the UNPHASED suite,28 was used for conditional analysis on DRB1. This program provides association tests conditioning on additional loci, which may already be associated and in linkage disequilibrium with the test loci. The EM algorithm is used to obtain maximium-likelihood estimates of haplotypes.
###end p 53
###begin p 54
###xml 56 62 56 62 <italic>et al.</italic>
###xml 62 64 62 64 <xref ref-type="other" rid="bib29">29</xref>
###xml 62 64 62 64 <sup><xref ref-type="other" rid="bib29">29</xref></sup>
###xml 191 193 191 193 <xref ref-type="other" rid="bib28">28</xref>
###xml 191 193 191 193 <sup><xref ref-type="other" rid="bib28">28</xref></sup>
LD were calculated from phenotypes according to Mattiuz et al.29 Estimates for Global D' and Cramer's V (measures of LD between multiallelic loci) were calculated using the COCAPHASE program.28
###end p 54
###begin title 55
Conflict of interest
###end title 55
###begin p 56
The authors declare no conflict of interest.
###end p 56
###begin p 57
###xml 692 700 <span type="species:ncbi:9606">patients</span>
This work was supported by the Italian Foundation for Multiple Sclerosis (FISM grants 2001/R/44, 2002/R/40 and 2005/R/10, 2008/R/11); CARIPLO Foundation, Regione Piemonte Ricerca Sanitaria Finalizzata (grants 2003, 2004, 2007, 2008), Regione Piemonte CIPE 2004, Ministry of Health (ricerca finalizzata grant 2004.80), Eastern Piedmont University (grants to SD and PMR). Compagnia di San Paolo (Turin), Fondazione CRT (Turin). DG and ES were supported by Fondazione Monzino, Ospedale Maggiore Policlinico and Ing. Cesare Cusan. NB was supported by a fellowship from FISM (2003/B/2). LB is a 'Biotechnology for Health' PhD student supported by a PhD Lagrange Fellowship. We are grateful to the patients and their parents and also to Professor Corrado Magnani for helpful discussion and to Dr Roberto Tosi for critical suggestions.
###end p 57
###begin article-title 58
Multiple sclerosis
###end article-title 58
###begin article-title 59
Environmental factors and multiple sclerosis
###end article-title 59
###begin article-title 60
HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe
###end article-title 60
###begin article-title 61
###xml 84 85 84 85 <sup>*</sup>
The multiple sclerosis-and narcolepsy-associated HLA class II Haplotype incluse DRB5*0101 allele
###end article-title 61
###begin article-title 62
HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation
###end article-title 62
###begin article-title 63
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis
###end article-title 63
###begin article-title 64
Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium
###end article-title 64
###begin article-title 65
A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis
###end article-title 65
###begin article-title 66
HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis
###end article-title 66
###begin article-title 67
Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease
###end article-title 67
###begin article-title 68
A second major histocompatibility complex susceptibility locus for multiple sclerosis
###end article-title 68
###begin article-title 69
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy
###end article-title 69
###begin article-title 70
SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians
###end article-title 70
###begin article-title 71
Further characterization of MHC haplotypes demonstrates conservation telomeric of HLA-A: update of the 4AOH and 10IHW cell panels
###end article-title 71
###begin article-title 72
###xml 31 36 <span type="species:ncbi:9606">human</span>
The haplotype structure of the human major histocompatibility complex
###end article-title 72
###begin article-title 73
Conserved extended haplotypes of the major histocompatibility complex: further characterization
###end article-title 73
###begin article-title 74
Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis
###end article-title 74
###begin article-title 75
Killer immunoglobulin-like receptors
###end article-title 75
###begin article-title 76
Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B
###end article-title 76
###begin article-title 77
Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project
###end article-title 77
###begin article-title 78
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
###end article-title 78
###begin article-title 79
Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A
###end article-title 79
###begin article-title 80
Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B
###end article-title 80
###begin article-title 81
Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease
###end article-title 81
###begin article-title 82
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis
###end article-title 82
###begin article-title 83
Defining the clinical course of multiple sclerosis: results of an international survey
###end article-title 83
###begin article-title 84
HLA class I DNA typing study
###end article-title 84
###begin article-title 85
Pedigree disequilibrium tests for multilocus haplotypes
###end article-title 85
###begin article-title 86
New approaches to the population genetics and segregation analysis of the HLA system
###end article-title 86
###begin p 87
###xml 38 42 38 42 <italic>A*02</italic>
###xml 44 49 44 49 <italic>Cw*05</italic>
###xml 54 61 54 61 <italic>DRB1*15</italic>
###xml 155 159 155 159 <italic>A*02</italic>
###xml 162 167 162 167 <italic>Cw*05</italic>
###xml 208 215 208 215 <italic>DRB1*15</italic>
ORs for the different combinations of A*02, Cw*05 and DRB1*15 alleles. The combination carrying the HLA-class I alleles conferring the highest protection (A*02+, Cw*05+) and without the class II risk allele (DRB1*15-) was used as a reference (OR=1) for the calculation of ORs. Figures in each bar correspond to the 95% CI.
###end p 87
###begin p 88
###xml 13 21 13 21 <italic>MOG-142L</italic>
###xml 23 31 23 31 <italic>HLA-A*02</italic>
###xml 36 46 36 46 <italic>HLA-Cw*05-</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Frequency of MOG-142L, HLA-A*02 and HLA-Cw*05-positive individuals among MS patients and controls
###end p 88
###begin p 89
Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio; NS, not significant.
###end p 89
###begin p 90
###xml 132 140 132 140 <italic>MOG-142L</italic>
###xml 186 195 186 195 <italic>HLA-A*02.</italic>
###xml 53 60 <span type="species:ncbi:9606">patient</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
Genotype frequencies (+/+, +/-, -/-) in the total MS patient sample vs total controls were 0.02, 0.26, 0.72 vs 0.04, 0.32, 0.64 for MOG-142L and 0.04, 0.29, 0.67 vs 0.07, 0.38, 0.55 for HLA-A*02. These frequencies did not deviate from Hardy Weinberg equilibrium either in MS patients or controls.
###end p 90
###begin p 91
###xml 32 40 32 40 <italic>MOG-142L</italic>
###xml 42 50 42 50 <italic>HLA-A*02</italic>
###xml 52 62 52 62 <italic>HLA-Cw* 05</italic>
###xml 67 74 67 74 <italic>DRB1*15</italic>
Logistic regression analysis of MOG-142L, HLA-A*02, HLA-Cw* 05 and DRB1*15 alleles
###end p 91
###begin p 92
Abbreviations: CI, confidence intervals; OR, odds ratio.
###end p 92
###begin p 93
Each marker in row is adjusted for markers in columns. In the last column the model includes all the markers.
###end p 93
###begin p 94
The bolded diagonal values contain the crude values for each marker.
###end p 94
###begin p 95
###xml 0 1 0 1 <italic>P</italic>
P-values are obtained from likelihood ratio test comparing the likelihood of the two-gene additive vs the single marker model considering as single marker the marker used for adjustment.
###end p 95
###begin p 96
###xml 73 79 73 79 <italic>DRB*15</italic>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
Linkage disequilibria among the three considered HLA-class I markers and DRB*15 in the control and in the MS patient population
###end p 96
###begin p 97
Abbreviation: MS, multiple sclerosis.
###end p 97
###begin p 98
###xml 44 45 44 45 <italic>r</italic>
###xml 45 46 45 46 <sup>2</sup>
Numbers represent D' (Lewontin's delta) and r2 (in brackets) values.
###end p 98
###begin p 99
###xml 0 1 0 1 <sup>*</sup>
###xml 1 2 1 2 <italic>P</italic>
###xml 9 11 9 11 <sup>**</sup>
###xml 11 12 11 12 <italic>P</italic>
###xml 23 26 23 26 <sup>***</sup>
###xml 26 27 26 27 <italic>P</italic>
*P<0.05, **P<0.005 and ***P<0.000001.
###end p 99
###begin p 100
###xml 27 35 27 35 <italic>HLA-A*02</italic>
###xml 40 49 40 49 <italic>HLA-Cw*05</italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Phenotypic combinations of HLA-A*02 and HLA-Cw*05 in MS patients and controls
###end p 100
###begin p 101
Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio.
###end p 101
###begin p 102
###xml 47 55 47 55 <italic>HLA-A*02</italic>
###xml 60 69 60 69 <italic>HLA-Cw*05</italic>
###xml 104 111 104 111 <italic>DRB1*03</italic>
###xml 125 132 125 132 <italic>DRB1*03</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Distribution of the phenotypic combinations of HLA-A*02 and HLA-Cw*05 in MS patients and controls among DRB1*03-positive and DRB1*03-negative individuals
###end p 102
###begin p 103
Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio; NS, not significant.
###end p 103

